Literature DB >> 16697727

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

Gioacchino Leandro1, Alessandra Mangia, Jason Hui, Paolo Fabris, Laura Rubbia-Brandt, Guido Colloredo, Luigi E Adinolfi, Tarik Asselah, Julie R Jonsson, Antonina Smedile, Norah Terrault, Valerio Pazienza, Maria Teresa Giordani, Emiliano Giostra, Aurelio Sonzogni, Giuseppe Ruggiero, Patrick Marcellin, Elizabeth E Powell, Jacob George, Francesco Negro.   

Abstract

BACKGROUND & AIMS: Steatosis is a frequent histologic finding in chronic hepatitis C (CHC), but it is unclear whether steatosis is an independent predictor for liver fibrosis. We evaluated the association between steatosis and fibrosis and their common correlates in persons with CHC and in subgroup analyses according to hepatitis C virus (HCV) genotype and body mass index.
METHODS: We conducted a meta-analysis on individual data from 3068 patients with histologically confirmed CHC recruited from 10 clinical centers in Italy, Switzerland, France, Australia, and the United States.
RESULTS: Steatosis was present in 1561 patients (50.9%) and fibrosis in 2688 (87.6%). HCV genotype was 1 in 1694 cases (55.2%), 2 in 563 (18.4%), 3 in 669 (21.8%), and 4 in 142 (4.6%). By stepwise logistic regression, steatosis was associated independently with genotype 3, the presence of fibrosis, diabetes, hepatic inflammation, ongoing alcohol abuse, higher body mass index, and older age. Fibrosis was associated independently with inflammatory activity, steatosis, male sex, and older age, whereas HCV genotype 2 was associated with reduced fibrosis. In the subgroup analyses, the association between steatosis and fibrosis invariably was dependent on a simultaneous association between steatosis and hepatic inflammation.
CONCLUSIONS: In this large and geographically different group of CHC patients, steatosis is confirmed as significantly and independently associated with fibrosis in CHC. Hepatic inflammation may mediate fibrogenesis in patients with liver steatosis. Control of metabolic factors (such as overweight, via lifestyle adjustments) appears important in the management of CHC.

Entities:  

Mesh:

Year:  2006        PMID: 16697727     DOI: 10.1053/j.gastro.2006.03.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  144 in total

1.  Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C.

Authors:  Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine
Journal:  Dig Dis Sci       Date:  2010-05-12       Impact factor: 3.199

2.  Understanding the role of PNPLA3 genetic variants in patients with chronic hepatitis C infection.

Authors:  Alessio Aghemo
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

3.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

4.  Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection.

Authors:  Donna L White; Peter A Richardson; Mukhtar Al-Saadi; Stephanie J Fitzgerald; Linda Green; Chami Amaratunge; Manvir Anand; Hashem B El-Serag
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

5.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

6.  Performance of liver stiffness measurements by transient elastography in chronic hepatitis.

Authors:  Giovanna Ferraioli; Carmine Tinelli; Barbara Dal Bello; Mabel Zicchetti; Raffaella Lissandrin; Gaetano Filice; Carlo Filice; Elisabetta Above; Giorgio Barbarini; Enrico Brunetti; Willy Calderon; Marta Di Gregorio; Roberto Gulminetti; Paolo Lanzarini; Serena Ludovisi; Laura Maiocchi; Antonello Malfitano; Giuseppe Michelone; Lorenzo Minoli; Mario Mondelli; Stefano Novati; Savino F A Patruno; Alessandro Perretti; Gianluigi Poma; Paolo Sacchi; Domenico Zanaboni; Marco Zaramella
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 7.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

8.  Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.

Authors:  Manuela G Neuman; Lawrence Cohen; Samir Zakhari; Radu M Nanau; Sebastian Mueller; Michelle Schneider; Charles Parry; Romina Isip; Helmut K Seitz
Journal:  Alcohol Alcohol       Date:  2014-05-09       Impact factor: 2.826

9.  Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.

Authors:  J-F Li; F Qu; S-J Zheng; H-L Wu; M Liu; S Liu; Y Ren; F Ren; Y Chen; Z-P Duan; J-L Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

10.  Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Authors:  Anna S Lok; James E Everhart; Raymond T Chung; Hae-Young Kim; Gregory T Everson; John C Hoefs; Joel K Greenson; Richard K Sterling; Karen L Lindsay; William M Lee; Adrian M Di Bisceglie; Herbert L Bonkovsky; Marc G Ghany; Chihiro Morishima
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.